Pregnancy worsens the morbidity of COVID-19 and this effect becomes more prominent as pregnancy advances

Tuğ, Niyazi; Yassa, Murat; Köle, Emre; Sakin, Önder; Köle, Merve; Karateke, Ateş; Yiyit, Nurettin; Yavuz, Emre; Birol, Pınar; Budak, Doğuş; Kol, Ömer; Emir, Edip

doi:10.4274/tjod.galenos.2020.38924

Cited by 26 publications

(35 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the US, ~5–9% of women with COVID-19 were identified to be pregnant [ 33 , 44 ]. Tug et al found more severe illness among pregnancies after 20 weeks gestational age [ 42 ].…”

Section: Maternal Infection With Sars-cov-2mentioning

confidence: 99%

“…Some complications may depend on the nature of the symptomatic and asymptomatic state [ 56 ]. Preterm delivery is relatively common, but the frequency has been considerably influenced by concerns for the pregnancy and hence by iatrogenic intervention [ 2 , 13 , 23 , 29 – 31 , 34 , 35 , 37 , 39 – 42 , 46 , 55 , 56 , 59 – 61 , 66 , 68 , 77 , 83 , 90 , 94 , 95 , 101 – 110 ]. Overall, the preterm delivery rate generally approaches 14–37%, but the frequency is as high as 75% when the maternal illness is severe.…”

Section: Maternal Infection With Sars-cov-2mentioning

confidence: 99%

“…Co-morbidities among pregnant patients with COVID-19 infection are common [ 115 ]. Co-morbidities are very common, however, in those with more aggressive illnesses, and these have especially included obesity and diabetes [ 1 , 2 , 12 , 14 , 19 , 28 , 30 , 31 , 33 , 34 , 38 – 40 , 42 , 68 , 79 – 81 , 88 , 89 , 94 , 96 , 105 , 110 , 116 ]. The anticipation of potential complications or the advanced nature of disease has led to a high rate of Caesarean section [ 1 – 3 , 10 , 21 – 23 , 25 , 29 – 32 , 35 , 38 – 42 , 51 , 55 , 56 , 59 , 60 , 68 , 74 – 77 , 82 , 87 , 94 , 101 , 105 , 107 , 109 – 115 , 117 – 129 ].…”

Section: Maternal Infection With Sars-cov-2mentioning

confidence: 99%

“…In a large American cohort, perinatal COVID-19 infection was estimated at 2.6% [ 108 ]. Most studies, however, report an infrequency of neonatal SARS-CoV-2 infection at birth or thereafter despite maternal infection of varying severity [ 1 – 3 , 13 , 16 , 19 , 20 , 22 – 25 , 29 , 30 , 35 , 38 , 41 , 42 , 46 , 47 , 51 , 55 , 59 – 61 , 66 , 68 , 72 , 82 , 90 , 100 , 104 – 107 , 109 , 110 , 112 , 113 , 117 – 120 , 123 , 126 , 128 , 129 , 139 , 162 , 168 , 185 , 188 , 191 , 193 , 196 , 197 , 213 , 222 , 228 , 237 – 244 ]. The latter has also been evident despite some newborn exposure to maternal breastfeeding [ 82 , 118 , 127 , 136 , 241 ].…”

Section: Antenatal or Neonatal Infection With Sars-cov-2mentioning

confidence: 99%

See 3 more Smart Citations

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Cimolai

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The maternal-fetal/newborn unit is established at risk for COVID-19 infection. This narrative review summarizes the contemporary and cumulative publications which detail maternal infection, antenatal and newborn infections, and maternal/fetal/newborn management and prevention. There is a wide spectrum of maternal disease, but the potential for severe disease albeit in a minority is confirmed. COVID-19 carries risk for preterm delivery. Pregnant females can suffer multisystem disease, and co-morbidities play a significant role in risk. Congenital infection has been supported by several anecdotal reports, but strong confirmatory data are few. No typical congenital dysmorphisms are evident. Nevertheless, placental vascular compromise must be considered a risk for the fetus during advanced maternal infections. Clinical manifestations of newborn infection have been mild to moderate and relatively uncommon. Proven antiviral therapy is of yet lacking. The mode of delivery is a medical decision that must include patient risk assessment and patient directives. Both presymptomatic and asymptomatic mothers and offspring can complicate infection control management with the potential for spread to others in several regards. In the interim, infections of the maternal-fetal-newborn unit must be taken seriously both for the disease so caused and the potential for further dissemination of disease.

show abstract

“…In the US, ~5–9% of women with COVID-19 were identified to be pregnant [ 33 , 44 ]. Tug et al found more severe illness among pregnancies after 20 weeks gestational age [ 42 ].…”

Section: Maternal Infection With Sars-cov-2mentioning

confidence: 99%

Section: Maternal Infection With Sars-cov-2mentioning

confidence: 99%

Section: Maternal Infection With Sars-cov-2mentioning

confidence: 99%

Section: Antenatal or Neonatal Infection With Sars-cov-2mentioning

confidence: 99%

See 2 more Smart Citations

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Cimolai

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

show abstract

“… 4 Pregnancy exacerbates the morbidity of COVID-19, with the effect potentiating as the pregnancy nears term. 4 , 6 , 7 Pregnancy increases the probability of hospital admission and intensive care. 6 , 8 There is, however, no difference in the risk of dying from COVID-19 between pregnant and non-pregnant women.…”

Section: Introductionmentioning

confidence: 99%

Corticosteroids Use in Pregnant Women with COVID-19: Recommendations from Available Evidence

Ssekandi¹,

Sserwanja²,

Olal³

et al. 2021

JMDH

View full text Add to dashboard Cite

Pregnant women experience immune system changes to accommodate and tolerate the growing foetus, these changes also increase their susceptibility to viral infections such as SARS-COV-2. COVID-19 in pregnancy increases the likelihood of hospital admission and intensive care compared to non-pregnant women. Early administration of low-dose corticosteroids to patients with acute respiratory distress syndrome can reduce all-cause mortality among such patients. However, during pregnancy, prolonged use of corticosteroids that readily cross the placenta like dexamethasone can negatively impact both the mother and foetus. Evidence is thus needed on the choice, timing, and duration for corticosteroids use among pregnant women with COVID-19. This article aims to provide evidence on corticosteroid use in pregnant women with COVID-19. The RECOVERY trial deduced that low-dose dexamethasone (6 milligrams) reduced mortality by up to one-third among COVID-19 patients on mechanical ventilation and one-fifth among those who received supplemental oxygen. Pregnant women in this trial received either oral prednisolone or intravenous hydrocortisone. Based on the RECOVERY trial findings, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends that pregnant women with moderate-to-severe COVID-19 receive oral prednisolone or intravenous hydrocortisone. However, currently, the World Health Organisation (WHO) does not explicitly specify which corticosteroid to use among pregnant women with moderate-to-severe COVID-19. We also note that there are no published articles on corticosteroid use among pregnant women with severe COVID-19 in Africa.

show abstract

Vitamin D status is not associated with clinical severity of COVID-19 in pregnant women

Tekin¹,

Yassa²,

Birol³

et al. 2021

Eur J Nutr

Self Cite

View full text Add to dashboard Cite

Pregnancy worsens the morbidity of COVID-19 and this effect becomes more prominent as pregnancy advances

Cited by 26 publications

References 13 publications

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Corticosteroids Use in Pregnant Women with COVID-19: Recommendations from Available Evidence

Vitamin D status is not associated with clinical severity of COVID-19 in pregnant women

Contact Info

Product

Resources

About